(Q82468356)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Inhibiting nonmuscle myosin II impedes inflammatory infiltration and ameliorates progressive renal disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

Jin Si

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Yan Ge

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Shougang Zhuang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Rujun Gong

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

published in

Laboratory Investigation

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

448-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20065948%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/labinvest.2009.142

16 January 2020

exact match

0 references

cites work

The human inflammatory response

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Inflammation and wound healing.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

The acute inflammatory reaction

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Points of control in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Mechanisms of inflammation and leukocyte activation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

The leukocyte cytoskeleton in cell migration and immune interactions

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Molecular signaling mechanisms of cell migration and invasion

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Specificity of blebbistatin, an inhibitor of myosin II

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

The structural basis of blebbistatin inhibition and specificity for myosin II

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

A single class II myosin modulates T cell motility and stopping, but not synapse formation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Myosin regulation in the migration of tumor cells and leukocytes within a three-dimensional collagen matrix

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Rapid leukocyte migration by integrin-independent flowing and squeezing

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Rho-kinase and myosin II activities are required for cell type and environment specific migration.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Nonmuscle myosin light-chain kinase mediates neutrophil transmigration in sepsis-induced lung inflammation by activating beta2 integrins

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

BCL6 suppresses RhoA activity to alter macrophage morphology and motility

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Myosin II regulates the shape of three-dimensional intestinal epithelial cysts

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Hepatocyte growth factor suppresses acute renal inflammation by inhibition of endothelial E-selectin

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Blebbistatin inhibits the chemotaxis of vascular smooth muscle cells by disrupting the myosin II-actin interaction.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Inhibition of pancreatic adenocarcinoma cellular invasiveness by blebbistatin: a novel myosin II inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Local macrophage proliferation in progressive renal injury.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Role of immunocompetent cells in nonimmune renal diseases

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Pathogenesis of renal injury in obstructive uropathy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Molecular basis of renal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Chronic kidney disease progression.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Pathophysiology of Progressive Nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Inflammatory cells during wound repair: the good, the bad and the ugly

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Increased systemic inflammation is a risk factor for COPD exacerbations

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

2,3-Butanedione monoxime (BDM) as a myosin inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Myosin IIA is required for cytolytic granule exocytosis in human NK cells

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

The actin-based motor protein myosin II regulates MHC class II trafficking and BCR-driven antigen presentation.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021

Mechanism of blebbistatin inhibition of myosin II

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2009.142

7 January 2021